Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on PLETHORA SOLUTIONS HOLDINGS. We currently have 6 research reports from 2 professional analysts.
|09Mar16 08:15||RNS||Scheme becomes Effective|
|08Mar16 16:44||RNS||Court Sanction of Scheme - Replacement|
|08Mar16 15:12||RNS||Scheme becomes Effective|
|08Mar16 11:59||RNS||Form 8.5 (EPT/RI) - Plethora Solutions PLC|
|08Mar16 07:30||RNS||Suspension - Plethora Solutions Holdings Plc|
|07Mar16 15:00||MKW||Form 8.3 - Plethora - Position Dealing Disclosure|
|07Mar16 13:36||RNS||Suspension of trading of Shares|
Frequency of research reports
Research reports on
PLETHORA SOLUTIONS HOLDINGS
PLETHORA SOLUTIONS HOLDINGS
Keep it up
31 Jul 15
Plethora is a specialty pharmaceutical company focused on commercialising PSD502™ (a treatment for male premature ejaculation) with strategic marketing partners and obtaining approval from the US FDA. The product received marketing authorisation from the European Medicines Agency (EMA) in November 2013 and was successfully partnered with Recordati in Europe and a few other territories. On the basis of DCF analysis, we value Plethora Solutions at £86.0m, underpinning our target price of 8.0p/share. Given the current share price, this implies 106.0% upside from current levels with a two-year horizon.
Initiation of coverage
31 Jul 15
Topic of the quarter: ‘Traditional headwinds looming large'. The UK Industrials sector has survived, indeed prospered, by focusing on high value added niches and growth markets. Unfortunately, one of these – the Oil & Gas segment – has been hit hard by the collapse in the oil price. Coupled with strong Sterling and weak demand in much of the developed world, the sector faces stiff headwinds for the balance of 2015 and into 2016.
Life Sciences Review - London calling to the faraway biotech: Now a bubble is declared and IPOs hail down
08 Jun 15
The British economy has 'cranked up several gears', according to the Confederation of British Industry (CBI), after a hiatus in the first quarter. Experts have passed off the slowdown in the first quarter of 2015 as a minor bump in the road for growth within the economy. The Office for National Statistics (ONS) in April 2015 revealed the UK economy had turned in the slowest quarterly growth for two years at 0.3 percent, driven by a widening trade deficit according to economists, which strengthened fears that the economy could well be heading for a slowdown. However, research conducted by the CBI put forward that business activity stepped up markedly in the three months to May, particularly led by strong growth in the professional services sector. Moreover, The Organisation for Economic Co-operation and Development (OECD) said that in spite of weakness in UK GDP in Q1 2015, growth has carried on at a "healthy pace", boosted by reasonable rises in consumption, employment and in real wages.
Consistently strong growth at a sensible price
24 Feb 17
In “Alice in Wonderland”, Lewis Carroll tells the story of a girl, who falls through a rabbit hole into a world populated by peculiar, anthropomorphic creatures. Here, Alice crosses swords with the Queen of Hearts, meets the Cheshire Cat and is invited to the "Mad Hatters” tea party, which she subsequently discovers is “stupid”.
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
£21m equity raise to accelerate growth
22 Feb 17
Blindly following what others do is often a recipe for disaster. However, when an army of ‘super smart’ fund managers snap-up a big holding in a rapidly expanding small-cap that owns ‘disruptive’ technology addressing multi-$billion markets, then it is usually worth taking note. This is exactly what has happened at Kromek, a next generation radiation detection firm. Having just successfully completed its oversubscribed £20m placing and £1m open offer at 20p/share - supported by esteemed investors such as Gervais Williams at Miton (largest shareholder at 19.0%) and Katie Potts (Herald 5.35%), as well as several others such as Schroders (5.0%) and Killik (4.1%).
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Anpario - Feed for growth
24 Feb 17
Anpario’s natural animal feed additive product offering is well placed to benefit from the increasing demand for animal protein and tightening regulations around antibiotic use as growth promoters. The group is in a transition phase, building strong commercial relationships with end users, which we believe should benefit the margin. Anpario’s geographical diversity is a key positive and with a strong balance sheet there is potential for acquisitive as well as organic growth. We initiate coverage with a 354p Target Price and a Buy recommendation ahead of FY results on 8th March.
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals